1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Species | Human |
Cat.No | ABC-TC3406 |
Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Product Category | Primary Cells |
Size/Quantity | 1 vial |
Cell Type | Mononuclear Cell |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Source Organ | Peripheral Blood |
Disease | Diffuse Large B-Cell Lymphoma |
Biosafety Level | 1 |
Storage | Liquid Nitrogen |
Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
Human Diffuse Large B-Cell Lymphoma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated) are derived from the peripheral blood of patients with newly diagnosed but untreated diffuse large B-cell lymphoma (DLBCL). Tumor B cells often harbor chromosomal abnormalities including translocations involving BCL6, MYC, or BCL2 detected by cytogenetic or FISH analysis.They are enriched by density gradient centrifugation, often accompanied by co-isolation of tumor B cells and reactive immune cells (T cells, NK cells, monocytes). High expression of B cell markers CD19, CD20; activated B-cell markers MUM1; germinal center markers BCL6; and proliferation markers such as Ki-67.Morphologically, these cells are highly heterogeneous. They carry rearranged immunoglobulin genes (IGH/IGK/IGL), highly express activated B cells or germinal center B cell subtype characteristic molecules (such as MUM1, BCL6), continue to proliferate through pathways such as NF-κB, PI3K/AKT, and secrete factors such as IL-10 and CXCL13 to reshape the immune microenvironment.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human Diffuse Large B-Cell Lymphoma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated) provides an important tool for analyzing DLBCL tumor heterogeneity, immune escape mechanisms, and resistance to targeted therapies (such as BTK inhibitors, PD-1/PD-L1 blockers), especially for longitudinal cohort analysis of newly diagnosed patient samples.